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This paper describes the selective and reproducible debenzylation of benzyloxypyrazinones using flow chemistry to
yield N-hydroxypyrazinones. Flow methodology enabled us to avoid overreduction of the compounds to pyrazin-2
(1H)-ones.
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1. Introduction
Hydroxamic acids, also occurring in bioactive compounds
from natural origin (e.g., aspergillic acid), are well-known for
their strong binding ability with many metal ions [1]. This
explains their potential to inhibit specific metal-containing
enzymes involved in human immunodeficiency virus [HIV]
[2–4] and cancer progression (histone deacetylases [HDACs],
mitochondrial membrane permeabilities [MMPs], ribonucleotide
reductase [RNR]) [5–7]. Our group has previously been working
on the design and synthesis of highly functionalized pyrazinones
[8–14]. In the current paper, we focus on our newly developed
synthesis of N-hydroxypyrazinones. These can be prepared via
the base catalyzed condensation of a glyoxal derivative with
either an α-amino hydroxamic acid (previous work) [15–20] or
an O-protected α-amino hydroxamic acid (this work). The latter
synthesis requires a deprotection step [21–24] but is warranted to
have a better compatibility with different classes of functional
groups as well as reaction conditions.
2. Results and Discussion
In order to avoid potential selectivity problems when prepar-
ing more complex systems (like the 3-carboxamide derivatives
described in this paper) and in order to avoid difficulties in
purification steps, we chose to work via the O-benzyl-protected
precursors. We recently reported on the synthetic procedures
that allow to prepare such 1-benzyloxypyrazin-2(1H)-ones from
simple starting materials elsewhere (Scheme 1) [25].
Reductive debenzylation of O-benzyl hydroxamates has been
reported before in the literature, though yields are sometimes low
and over-reduction to amides is a known problem [21, 26–30];
however, an appropriate catalyst system (e.g., Pd–BaSO4) can
solve this problem in a number of cases [31–33]. Our debenzy-
lation studies commenced with 1-benzyloxypyrazin-2(1H)-one
(3a) using batch chemistry (Table 1) with hydrogen gas and
different palladium catalysts (e.g., Pd–C and Pd–BaSO4). This
showed that the hydrogenolysis is fast and more selective for the
desired compounds 4a with the less reactive Pd-based catalysts at
high temperature (Entry 6, Table 1). Since a characteristic ultra-
violet (UV) absorption maximum of the core pyrazinone scaf-
folds is present in the range of 320–370 nm (depending on pH)
[34–36], a high-performance liquid chromatography–ultraviolet–
mass spectrometry (HPLC–UV–MS) method has been used to
quantify the relative conversion and selectivity of the reactions in
this study. It is based on the integration of relative peak areas of
reactant and product/byproduct at the indicated wavelength (for
details, see Supporting Information).
However, when the same conditions were applied to 1-ben-
zyloxypyrazin-2(1H)-one 3-carboxamide derivatives 3g–zb,
removal of the benzyl group most of the time was met with
failure due to over-reduction. An excellent selectivity of 4h
over 5h (91%, HPLC–UV–MS, 350 nm) once was obtained
when performing the debenzylation of 3h with 5% Pd–BaSO4
(unreduced form) under hydrogen gas (1 bar, balloon). More-
over, the selectivity obtained in all these reactions was not
reproducible even with the same substrates. Efficient control
of the contact time between reagent and products and the
catalyst seemed to be of the utmost importance. Therefore, we
decided to switch from conventional batch hydrogenation con-
ditions to flow technology using a catalytic transfer hydrogena-
tion where residence times are more easily tuned and controlled.
The reactions under flow conditions were performed in the
microflow system using a catalyst reactor (Chemtrix) and a back-
pressure regulator (Figure 1).We carefully screened and optimized
the factors that could affect the selectivity and the conversion of the
debenzylation process under flow conditions.
Product solubility is one of themost critical factors andmay be a
limitation of flow chemistry in general [37–39]; the formation of
precipitate during the reaction may block the micro-channels and
build up pressure, which could break the glass reactor [40, 41].
After screening different solvents, we found methanol being the
best candidate: it could properly dissolve reasonable amounts of
most of our substrates as well as the resulting debenzylated prod-
ucts. Besides that, its polarity is also favorable for the hydrogenol-
ysis. Ethanol and isopropanol were able to dissolve the substrate
benzyl hydroxamates but not the hydroxamic acid products.
Many hydrogen donors can be used in catalytic transfer
hydrogenation, such as formic acid and its salts, isopropanol,
cyclohexene, cyclohexadiene, hydrazine, phosphinic acid, etc.
[42–44]. In situ hydrogen formation in the reaction mixture
increases the gas–liquid–solid phase interaction, helps to control
the stoichiometry of the reagents, and, most importantly, helps to
avoid the risk of fire and explosion associated with using hydrogen
gas (especially when dealing with larger scale synthesis). We used
ammonium formate, which showsmore advantages in comparison
to the others [43, 45–49], as a hydrogen donor. Ammonium for-
mate acts as a hydrogen equivalent that may be presented either in
the adsorbed form on palladium or in the palladium hydride form
[49]. Study on the decomposition of ammonium formate shows
that it brings to the reaction not only hydrogen but also ammonia
and carbon dioxide [45, 50, 48, 49]. These gases were observed as
bubbles formed downstream of the backpressure regulator.
The pressure in the reaction mixture was fixed using a back-
pressure regulator set at 5 bar. This also allowed us to work
above the boiling point of methanol up to 110 °C.
An appropriate catalyst was needed for the debenzylation,
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Horn and Cerato–Noyerie recently reported the development of
a convenient in situ PdCl2-based catalyst for hydrogenation in
glass microreactors [51]. We found an alternative Pd source
with appropriate particle size specifications in the form of
SiliaCat® DPP-Pd which has been shown to be a useful catalyst
for many kinds of Pd-catalyzed reactions (Heck, Sonogashira,
Kumada, Suzuki, Stille reactions, and Buchwald aminations) in
flow [52–54]. This catalyst was used in the optimization of
temperature and residence time for the debenzylation in flow
using the model system 1-benzyloxy-N,N-diethyl-5,6-dimethyl-
pyrazin-2(1H)-one-3-carboxamide (3h) with ammonium for-
mate in methanol (Scheme 2).
Reagents and conditions: 3h (0.25 mmol, 0.1 M, 2.5 mL,
1.0 equiv.), HCO2NH4 (0.5 mmol, 0.2 M, 2.5 mL, 2.0 equiv.),
SiliaCat® DPP-Pd (12 mg).
The optimization was performed in the setup described in
Figure 1 and Scheme 2. The two solutions were pumped into the
reactor containing SiliaCat® DPP-Pd catalyst. Product/byproduct
and starting material (if not fully converted) passed through the
backpressure regulator before being collected in vials, which were
used for HPLC–UV–MS analysis. Temperature (20–110 °C) and
residence time (Rt 14–36 s) were varied, and the results are sum-
marized in Figure 2 (temperature effect) and Figure 3 (residence
time effect).
As shown in Figure 2, the reaction only occurs with accept-
able conversions above 60 °C, the temperature above which
ammonium formate efficiently decomposes in the presence of
Pd. The conversion is more or less constant and complete in a
wide range of temperatures (80–110 °C) at a residence time of
14 s without losing selectivity for the formation of the desired
product (4h, N–OH form, 97–98%) over the over reduced
product (5h, N–H form, 1–2%).
At 80 °C, complete conversion is seen with the residence
time of 14 s. Increasing the residence time favors the formation
of over reduced species (Figure 3). The same trend is observed
at higher temperatures, with relatively larger amounts of over
reduced compounds formed at longer residence time (up to
5.5% at 110 °C using a residence time of 36 s).
Based on these results, it is considered that the optimal
condition for debenzylation of 1-benzyloxypyrazin-2(1H)-one
3-carboxamide 3h in this flow setup with HCO2NH4/SiliaCat®
DPP-Pd inmethanol are a temperature above 80 °C and a residence
time of 14 s. Using these conditions, the turnover number of the
catalyst was determined to be at least 100 in a long-run debenzy-
lation of compound 3h (for details, see Supporting Information).
For testing the further scope of the procedure, we preferred to
perform the reactions at 100 °C since the higher temperature
would be beneficial in keeping all of the reaction partners in
solution. In this way, we managed to convert the compounds
3a–zb into a library of aspergillic acid-like hydroxamic acids in
Figure 1. Schematic representation for the debenzylation experimental
setup in flow
Scheme 1. Synthesis of 1-benzyloxypyrazin-2(1H)-ones
Table 1. Batch debenzylation of 1-benzyloxypyrazin-2(1H)-one (3a)
Entry Catalyst Condition Selectivity (%)a
4a 5a
1 5 % Pd–C 2 bar/rt/5 min 0 100
2 5 % Pd–C 1 bar/rt/10 min 25 75
3 5 % Pd–C 1 bar/rt/30 min 20 80
4 5 % Pd–C 1 bar/reflux/5 min 60 40
5 5 % Pd–BaSO4
b 1 bar/reflux/5 min 80 20
6 5 % Pd–BaSO4
c 1 bar/reflux/5 min 95 5
Reagents and conditions: 3a (0.1 mmol, 0.1 M), H2 (in a Parr apparatus
or with a balloon), palladium catalyst (5 %wt.).
aQuantitative conversion (quantification at 350 nmvia RPHPLC–UV–MS).
b Pd–BaSO4 reduced form.
c Pd–BaSO4 unreduced form.
Scheme 2. Debenzylation of representative precursor 3h in flow
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good to excellent yields (Table 2). In case of secondary amides
3i,o,r,t,x, yield and selectivity were improved dramatically
when decreasing the residence time to 10 s (Entry 9, 15, 19,
21, and 25, Table 2). Moreover, N-debenzylation of the carbox-
amide was not observed in our examples 3i–k (Entry 9–11,
Table 2). All the compounds 4a–zb show satisfactory analytical
data and test positive for the hydroxamate function in aqueous
ferric chloride solution (dark red color) and aqueous copper (II)
acetate solution (green color).
To test the scalability of the protocol, a follow-up experiment
was performed with compound 3h in a milliflow system (X-Cube)
equipped with a catalyst cartridge containing SiliaCat® DPP-Pd
(188 mg). Excellent conversion (96%) and selectivity (98%) were
obtained at a flow rate of 3.0 mL/min (for details, see Supporting
Information). In this way, 2.2 g of 3h has been converted into the
corresponding 1-hydroxypyrazin-2(1H)-one 3-carboxamide 4h
(1.4 g, 90% isolated yield) at 110 °C, 30 bar backpressure with a
flow rate of 3.0 mL/min.
In summary, with the application of flow technology and
catalytic transfer hydrogenation, we have succeeded in deliver-
ing a reproducible methodology for the selective debenzylation
of O-benzyl protected cyclic hydroxamates, with a potential of
scaling up from milligram scale to gram scale on suitable flow
operations. This solved reproducibility problems experienced
earlier using batch reaction conditions and finally allowed the
efficient, safe, and reproducible synthesis of a library of 28
N-hydroxypyrazin-2(1H)-one analogues.
3. Experimental Section
3.1. General Experimental Methods. All reagents were
obtained from commercial sources and used as purchased
without further purification. All solvents were analytical or HPLC
or LC–MS grade and were used as supplied. Palladium-based
catalysts were purchased from Sigma-Aldrich. SiliaCat® DPP-
Pd was bought from SiliCycle and sieved one more time to obtain
the particle size 80–120mesh before packing into themicroreactor.
Debenzylation reactions under batch conditions weremagnetically
stirred under a hydrogen atmosphere (balloon) or shaken in a Parr
hydrogenation apparatus. Reactions under flow conditions were
performed on a Labtrix® Start system and an X-Cube system. The
course of all reactions was monitored by HPLC–UV–MS (Prevail
C18 2.1×150 mm 3 μm column, quadrupole ion trap, 350 or
375 nm) using atmospheric pressure ionization electrospray
(API–ES) in positive mode. Preparative HPLC (Luna C18 21.2×
150 mm 5 μm column, photodiode array detector) was used to
purify the N-hydroxypyrazin-2(1H)-one products. Solvents were
evaporated in a rotavapor at 40 °C. A bench-top lyophilizer was
used to dry water-containing samples. Yields refer to yields of
isolated compounds after chromatography; selectivities were
determined on the crude mixtures by HPLC–UV–MS at the
indicated wavelength. Nuclear magnetic resonance (NMR)
spectra were recorded on 400 MHz and 600 MHz FT-NMR
spectrometers in the indicated deuterated solvents; chemical
shifts are expressed in δ scale (ppm) using tetramethylsilane as
an internal standard, and coupling constants J are reported in
Hertz (Hz). Low-resolution MS spectra were recorded on the
LC–APCI–MS in positive mode. High-resolution MS spectra
were recorded on a micrOTOF-Q instrument using electro-
spray ionization (ESI) in positive mode.
3.2. Flow Systems. The Labtrix® Start system (Chemtrix) is
equippedwith a reactor holder, a temperature controller, a standard
syringe pump, gastight syringes (1.0 and 2.5 mL), polytetra-
fluoroethylene (PTFE) tubing (1/32″ OD×0.009″ ID), an IDEX
Figure 2. Temperature effect on debenzylation of 3h in flow (at residence time of 14 s, about 6 dead volumes were allowed to pass after modifying the
temperature before the conversions were determined, conversion at 350 nm, HPLC–UV–MS)
Figure 3. Residence time effect on debenzylation of 3h in flow (at different temperatures, conversion at 350 nm, HPLC–UV–MS)
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5 bar backpressure regulator, and a catalyst reactor model 3026
(Chemtrix). The schematic diagram of the experiment setup is
shown in Figure 1. The X-Cube system (ThalesNano) is equipped
with twoHPLCpumps (flow rate 0.1–3.0mL/min), inlet and outlet
pressure systems (max 150 bar), a heater unit, a SiliaCat®DPP-Pd
CatCart column, stainless steel tubing (0.5 mm ID), and PTFE
tubing (1/8″ OD×1/16″ ID).
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